CASTILLO-RAMA, M. et al. Long term molecular remission of chronic myeloid leukemia in a hepatitis C virus renal transplant patient with asociated risk factors. []. , 29, 6, pp.604-607. ISSN 1989-2284.

Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors.

: Chronic myeloid leukemia; renal transplant.

        · |     · |     · ( pdf )